“Great scientific strides can be made by solving small but fundamental problems.”

Suzanne Saffie-Siebert

SiSaf is delivering on the promise of RNA therapeutics to transform the treatment of disease

SiSaf has developed the Bio-Courier® platform of silicon stabilized hybrid lipid nanoparticles to dramatically improve the stabilization and delivery of RNA based therapeutics and vaccines. We are using its proprietary next-generation hybrid nanoparticles to advance our in-house pipeline of RNA therapeutics for rare genetic skeletal disorders, alongside partnering with specialty pharmaceutical companies to maximize the potential applications of its Bio-Courier platform.

Being a bioabsorbable silicon-lipid hybrid, Bio-Couriers, optimize the delivery of nucleic acid-based therapeutics, through superior stability and protection of the RNA payload and lipid surface while reducing the potential of adverse immune events.

Founded by entrepreneur and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is headquartered in Guildford, UK, with fully integrated state-of-the-art research labs, pilot manufacturing and bioanalytical facilities.

SiSaf is a private company supported by venture capital investors including Vickers Venture Partners & UK Future Fund.

HISTORY

The company’s Founder and CEO, Dr Suzanne Saffie-Siebert, had the vision of a new generation of hybrid drug delivery technology that would combine lipid nanoparticles with biodegradable silicon. This vision was rooted in years of experience with both liposomes and silicon, having completed her PhD thesis on the incorporation of plasmid DNA into liposomes and having helped pioneer drug delivery with porous silicon at pSiMedica, a spin-out of Qinetiq. She hypothesized that silicon could be used to stabilize lipid nanoparticles and that in turn lipids would help control the biodegradation of Silicon. With this vision, SiSaf began operating in 2008 with funding from Invest NI and the investment arm of the University of Ulster.

 

Over its foundational years the team was dedicated to developing and optimising the new hybrid technology and generating safety and efficacy data. These data enabled SiSaf in 2016 to secure Series A funding to pivot from a University-based pre-seed company to an emerging biopharma company commercialising its RNA delivery technology.

The company also formed a partnership with Croda International plc and launched a skincare subsidiary in the U.S.

In 2019, the company focused its R&D activities on gene-based medicines with a pipeline developed through a partnership with Avellino Labs USA to co-develop topical gene therapies for corneal dystrophies, and entered into a license and research agreement with the University of L’Aquila, Italy, for the development of siRNA therapies for rare skeletal diseases.

Management team

 
Dr Suzanne Saffie-Siebert
Chairwoman & Chief Executive Officer

I believe good science equals good business. SiSaf is the culmination of more than 25 years that I spent in drug delivery research and senior management.

Linked In
plus
 
Dr Michael Welsh
Chief Scientific Officer

As an immunologist, I spent two decades understanding the modes of action in disease and looking for treatments. I’ve seen how ProSilic bio-courier technology can intervene and cure.

Linked In
plus
 
Dr Nessim Torabi-Pour
Chief Technical Officer

My 20 years’ experience in analytical techniques and drug delivery research helped boost the development of ProSilic  right from the start.

Linked In
plus
 
Richard Scarrott
Chief Financial Officer

SiSaf has a fantastic opportunity to develop and commercialise its Bio-Courier technology for a range of therapies, but particularly its potential in gene therapy.   As an experienced finance professional, it is great to be able to work with Suzanne and the team to realise that value growth.

Linked In
plus
 
Charles Weatherstone
Chief Marketing Officer

Over my many years in health care marketing I’ve had lots of drug delivery systems cross my desk but all of them fell short, until I was introduced to SiSaf. I was so impressed I joined the company.

Linked In
plus
 
Dr Spiros Servos
Head of Business Development

I am particularly excited about the development of affordable therapies for autosomal dominant diseases with Bio-Couriers. I believe non-viral gene therapies have the potential to become standard clinical practise.

Linked In
plus

Advisors

 
Prof. Anna Maria Teti
Full Professor of Histology, University of L’Aquila School of Medicine

Coming Soon

Linked In
plus
 
Prof. Michael J Econs
Distinguished Professor of Medicine and Medical and Molecular Genetics

Distinguished Professor of Medicine and Medical and Molecular Genetics and is the director of the division of Endocrinology and Metabolism. Indianan University School of Medicine

plus
 
Prof. Libero Italo Giannola
Professor of Applied Pharmaceutical Chemistry

Professor of Applied Pharmaceutical Chemistry. Professor of Pharmaceutical Technologies. University of Palermo (UNIPA)

Linked In
plus
 
Prof. Tara Moore
Director of the Biomedical Research Institute at Ulster University

Director of the Biomedical Research Institute at Ulster University

Linked In
plus
 
Prof. John Marshall
Frost Professor of Ophthalmology and Chairman of the Academic Department of Ophthalmology at St. Thomas’ Hospital

Frost Professor of Ophthalmology and Chairman of the Academic Department of Ophthalmology at St. Thomas’ Hospital

plus
 
Todd E. Schlesinger
MD, FAAD, FASMS

Medical Director, Board-Certified Dermatologist, Fellow American Society for Mohs Surgery.

Linked In
plus

Board

 
Dr Suzanne Saffie-Siebert
Chairwoman & Chief Executive Officer

I believe good science equals good business. SiSaf is the culmination of more than 25 years that I spent in drug delivery research and senior management.

Linked In
plus
 
Dr. Elkhalil Binebine
Board Member

I led the Series A investment in SiSaf not just because of their innovative platform technology, but also the passion of the people behind it.

plus
 
Dr Damian Kelly
Board Member

As Croda’s Head of Global R&D, I value the  expertise and dedication that SiSaf’s team bring to their breakthrough technology.

Linked In
plus
 
Dr Finian Tan
Board Member

Ever since I led the investment in Baidu and became its largest shareholder on behalf of Dfj Eplanet, I’ve been on the lookout for companies with game changing technologies. SiSaf is one of those game changers.

Linked In
plus
 
Eric M. Attias
Board Member

During my 25 years in the financial industry, SiSaf is one of the most exciting biotech companies I’ve come across.

Linked In
plus
 
Neil Simms
Board Member

I’m extremely  proud to have spotted the company’s global potential in its early days.

Linked In
plus
 
Tim Brundle
Board Member

As Director of Research and Impact for one of SiSaf’s first investors, I’ve followed the company’s extraordinary progress from day one.

Linked In
plus